Ischemic heart disease (IHD) is the leading cause of death and disability worldwide. The high mortality rate in patients with IHD is primarily due to the presence of comorbid conditions that can mutually aggravate each other’s course and significantly worsen the prognosis. The most common concomitant pathology in patients with IHD is considered to be chronic heart failure (CHF). The combination of IHD and CHF reduces the quality of life of patients and increases the risk of death. In this regard, drug therapy in this clinical situation should be not only optimal in terms of safety, but also effective. However, the existing approaches to the treatment of IHD, including in the presence of CHF, do not demonstrate the desired results in reducing mortality and the incidence of cardiovascular events, therefore, there is a need to improve the tactics of managing patients with IHD and CHF. Currently, there is convincing evidence that metabolic disorders in the myocardium, including mitochondrial dysfunction, play an important role in the development and progression of IHD and CHF. In this regard, metabolic therapy aimed at increasing the energy efficiency of the myocardium is of particular interest in the treatment of patients of this category. One of the most studied metabolic drugs is trimetazidine. The aim of this review was to study the literature data on the possibility of using trimetazidine in the treatment of patients with a combination of IHD and CHF.Keywords: ischemic heart disease, antianginal therapy, heart failure, metabolic disorders, metabolic therapy, trimetazidine

Keywords: antianginal therapy, metabolic therapy, metabolic disorders, trimetazidine, ischemic heart disease, heart failure